Table 1.

In vivo pharmacokinetics data for BPN-14136 following intravenous (i.v.) and oral (p.o.) administration in mice

Dosing cohorts consisted of three groups of drug-naive adult male CD-1 mice. Mean BPN-14136 concentrations per time point were used to calculate the composite PK parameters by non-compartmental analysis using the WinNonlin program.

Route	Dose	Tmaxa	Cmaxb	T½ c	Vssd	Cle	AUClastf	AUCINFg	%Fh
	mg/kg	h	ng/ml	h	ml/kg	ml/h/kg	h·ng/ml	h·ng/ml
i.v.	2	0.083i	10,930	5.6	233	39.9	49,960	50,140	NAj
p.o.	5	2	11,027	5.0	NAj	NAj	129,300	129,400	103.2

^a Time of maximum observed concentration of BPN-14136 in plasma.

^b Peak plasma concentration of BPN-14136 is shown.

^c Apparent half-life of the terminal phase of elimination of compound from plasma is shown.

^d Volume of distribution is at steady state.

^e Cl is total body clearance.

^f Area under the plasma concentration versus time curve from 0 to the last time point that compound was quantifiable in plasma is shown.

^g Area under the plasma concentration versus time curve from 0 to infinity is shown.

^h Bioavailability is F = (AUC_INFpo × dose_iv) ÷ (AUC_INFiv × dose_po).

ⁱ First plasma collection time is shown.

^j NA means not applicable.